158 related articles for article (PubMed ID: 19594741)
1. Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial.
Yee DS; Lowrance WT; Eastham JA; Maschino AC; Cronin AM; Rabbani F
BJU Int; 2010 Jan; 105(2):185-90. PubMed ID: 19594741
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
Debruyne FM; Witjes WP
Mol Urol; 2000; 4(3):251-6;discussion 257. PubMed ID: 11062381
[TBL] [Abstract][Full Text] [Related]
3. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I; Fujisawa M
Anticancer Res; 2006; 26(2B):1583-7. PubMed ID: 16619575
[TBL] [Abstract][Full Text] [Related]
4. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
Miyake H; Sakai I; Inoue TA; Hara I; Fujisawa M
Urol Int; 2006; 77(2):122-6. PubMed ID: 16888415
[TBL] [Abstract][Full Text] [Related]
5. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer.
Witjes WP; Schulman CC; Debruyne FM
Urology; 1997 Mar; 49(3A Suppl):65-9. PubMed ID: 9123739
[TBL] [Abstract][Full Text] [Related]
6. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
[TBL] [Abstract][Full Text] [Related]
7. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
8. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.
Tosco L; Laenen A; Briganti A; Gontero P; Karnes RJ; Albersen M; Bastian PJ; Chlosta P; Claessens F; Chun FK; Everaerts W; Gratzke C; Graefen M; Kneitz B; Marchioro G; Salas RS; Tombal B; Van den Broeck T; Moris L; Battaglia A; van der Poel H; Walz J; Bossi A; De Meerleer G; Haustermans K; Van Poppel H; Spahn M; Joniau S
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):407-412. PubMed ID: 28485390
[TBL] [Abstract][Full Text] [Related]
9. Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer.
Silberstein JL; Poon SA; Sjoberg DD; Maschino AC; Vickers AJ; Bernie A; Konety BR; Kelly WK; Eastham JA
BJU Int; 2015 Jul; 116(1):50-6. PubMed ID: 24552276
[TBL] [Abstract][Full Text] [Related]
10. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109.
Berglund RK; Tangen CM; Powell IJ; Lowe BA; Haas GP; Carroll PR; Canby-Hagino ED; deVere White R; Hemstreet GP; Crawford ED; Thompson IM; Klein EA
Urology; 2012 Mar; 79(3):633-7. PubMed ID: 22386416
[TBL] [Abstract][Full Text] [Related]
11. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy.
Zhao B; Yerram NK; Gao T; Dreicer R; Klein EA
Urol Oncol; 2015 Apr; 33(4):164.e19-23. PubMed ID: 25665510
[TBL] [Abstract][Full Text] [Related]
13. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era.
Isbarn H; Wanner M; Salomon G; Steuber T; Schlomm T; Köllermann J; Sauter G; Haese A; Heinzer H; Huland H; Graefen M
BJU Int; 2010 Jul; 106(1):37-43. PubMed ID: 20002667
[TBL] [Abstract][Full Text] [Related]
14. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study.
Cookson MS; Sogani PC; Russo P; Sheinfeld J; Herr H; Dalbagni G; Reuter VE; Begg CB; Fair WR
Br J Urol; 1997 Mar; 79(3):432-8. PubMed ID: 9117227
[TBL] [Abstract][Full Text] [Related]
15. Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?
Boorjian SA; Bianco FJ; Scardino PT; Eastham JA
BJU Int; 2005 Oct; 96(6):773-6. PubMed ID: 16153197
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy.
Pu XY; Wang XH; Wu YL; Wang HP
J Cancer Res Clin Oncol; 2007 Aug; 133(8):555-62. PubMed ID: 17457611
[TBL] [Abstract][Full Text] [Related]
17. [8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].
Tabata K; Satoh T; Matsumoto K; Fujita T; Irie A; Iwamura M; Yanagisawa N; Matsuda D; Muramoto M; Kadowaki K; Suyama K; Shoji K; Koh H; Kawakami T; Okayasu I; Egawa S; Baba S
Nihon Hinyokika Gakkai Zasshi; 2006 Jul; 97(5):712-8. PubMed ID: 16898594
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.
Miyata Y; Nakamura Y; Yasuda T; Matsuo T; Ohba K; Furusato B; Fukuoka J; Sakai H
Prostate; 2017 Oct; 77(14):1408-1415. PubMed ID: 28845514
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant hormonal therapy in carcinoma of the prostate.
Lee HH; Warde P; Jewett MA
BJU Int; 1999 Mar; 83(4):438-48. PubMed ID: 10210568
[TBL] [Abstract][Full Text] [Related]
20. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
